A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects With Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Gastrointestinal Tumors

Trial Profile

A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects With Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Gastrointestinal Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs CGX 1321 (Primary) ; Pembrolizumab
  • Indications Colorectal cancer; Gastrointestinal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Curegenix
  • Most Recent Events

    • 09 Apr 2018 Phase 1b portion of the study added: Study of CGX1321 in combination with pembrolizumab in subjects with advanced gastrointestinal tumors and advanced colorectal tumors.
    • 09 Apr 2018 Planned number of patients changed from 71 to 72.
    • 09 Apr 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top